Skip to main content


Table 1 Characteristics of anti-CD20 mAbs

From: Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment

Generation Format Drug Special features FDA-approved indications
1st Murine–human chimeric Rituximab Immunogenicity occurs due to chimeric nature NHL, CLL, RA, GPA, MPA
2nd Humanized Ocrelizumab Binds an overlapping epitope region as rituximab. Increased binding affinity. Enhanced ADCC and less CDC compared to rituximab [8, 32] RRMS and PPMS
Veltuzumab Complementarity-determining regions are similar to rituximab. Greater binding avidity and effect on CDC than rituximab [8] Orphan status designation for ITP and pemphigus
Obinutuzumab Binds to an epitope on CD20 that partially overlaps with that of rituximab. Greater ADCC than rituximab. Unlike rituximab, obinutuzumab does not stabilize CD20 in lipid rafts and thus has less CDC. More effective at direct B cell apoptosis [63] With chlorambucil for previously untreated CLL
Fully human Ofatumumab Binds to an epitope distinct from that recognized by rituximab, ocrelizumab, veltuzumab, and obinutuzumab. Greater CDC and apoptosis than rituximab [17] Refractory or conventional therapy-intolerant CLL